ALFA FinderBSE filing, NSE: MCX. Summary written from the filing by ALFA Finder's alert engine.
Multi Commodity Exchange of India Ltd: key numbers
- Share price
- ₹3,617.60
- Market cap
- ₹92,246 Cr
- Revenue (annual)
- ₹2,302 Cr
- Net profit (annual)
- ₹1,332 Cr
- P/E (TTM)
- 51.3×Sector 20.8×
- Promoter holding
- 0.00%+0.00% QoQ
- FII holding
- 27.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Multi Commodity Exchange of India Ltd
All →Multi Commodity Exchange of India Earnings Call Transcript: Key Takeaways
H1 FY27 PAT ₹868 Cr (+117%) on revenue ₹1,501 Cr (+101%); no guidance given, management declines margin projections.
Multi Commodity Exchange of India Management Change
MCX's shareholders approved Mohan Shenoi's re-appointment as Non-Independent Director at the 17 September 2026 AGM. SEBI approved the re-appointment on 5 November 2026.
Multi Commodity Exchange of India Investor Presentation: Key Takeaways
Q2 FY27: operating revenue ₹800 Cr (+113.9% YoY), PAT ₹455 Cr (+130.8%), EBITDA margin 78.0%. H1 PAT ₹868 Cr (+116.4%). No explicit guidance given.
Multi Commodity Exchange of India Results Update
MCX reported H1FY27 consolidated revenue of ₹1,502 crore, up 100.8% YoY, and PAT of ₹868 crore. Q2FY27 PAT rose 130.8% YoY to ₹455 crore.
Multi Commodity Exchange of India Q2 FY27 Results: Net Profit ₹454.6 Cr, Up 130.2% YoY
Multi Commodity Exchange of India Ltd reported revenue from operations of ₹799.7 Cr (+113.7% YoY) and net profit of ₹454.6 Cr (+130.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹454.6 Cr · +130.2% YoY
Multi Commodity Exchange of India Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2026, as required by SEBI Regulation 31(1)(b).
Other product launch announcements
All →Jeena Sikho Lifecare Product Launch
Jeena Sikho Lifecare launched ten new Ayurvedic healthcare products in the domestic market on November 11, 2026. The filing gives product-wise details under SEBI product-launch disclosure rules.
HCL Technologies Product Launch
HCLTech launched a pre-configured semiconductor PLM solution built on PTC Windchill, developed in collaboration with PTC. The release states no contract value or deal size, and the launch is a new product offering.
Morepen Laboratories Product Launch
Morepen launched Desloratadine Tablets USP 5 mg, its first US prescription generic, through subsidiary Morepen Bio Inc. It also filed a Sitagliptin ANDA with the US FDA.
AstraZeneca Pharma India Product Launch
AstraZeneca Pharma India will launch Datverzo, Datopotamab Deruxtecan, in India in November 2026. The drug holds DCGI import and market permission for HR-positive, HER2-negative breast cancer.
Raama Finance Product Launch
Raama Finance launched 'Rupya Lelo', a digital lending platform offering instant personal loans, on October 6, 2026. The product is available only in India, and no loan amount or financial figure is disclosed.
Puravankara Product Launch
Puravankara will launch the residential project Purva Cityspire Phases 1, 2 and 3 in Ernakulam on 15 November 2026. The project is RERA-registered and is being developed by two wholly owned subsidiaries.